|
|
Californians And Minnesotans Help Produce As Well As Benefit From Lifesaving Therapies
September 1, 2010
ANNAPOLIS, MD (September 1, 2010) – This month, Californians and Minnesotans are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that make the creation of these unique therapies possible. California and Minnesota are recognizing September 2010 as “Plasma Protein Therapies Month,” helping to raise awareness for the rare, genetic diseases treated with the therapies and to value the contributions of voluntary plasma donors in the states.
|
|
more >>
|
| |
|
|
DENGUE VIRUS AND PLASMA PROTEIN THERAPIES
August 2, 2010
PPTA members are committed to providing safe and effective therapies. PPTA understands that people who rely on plasma protein therapies may have concerns about the possible transmission of Dengue virus through these therapies. PPTA considered available information on this virus and the available data clearly indicate that plasma protein therapies as manufactured by PPTA member companies provide high margins of safety against Dengue transmission.
|
|
more >>
|
| |
|
|
Plasma Protein Therapeutics Industry is Proud of its Commitment to Save Lives
July 29, 2010
“The documentary film Bad Blood: A Cautionary Tale, chronicles a tragic time in our country’s history that should never be forgotten and should never happen again. It depicts the struggle 25 years ago of government officials, physicians, scientists, patient organizations and others to identify an unknown virus, eventually known as HIV. In the midst of that struggle, people with hemophilia became infected.
|
|
more >>
|
| |
|
|
PPTA NOMINATES TWO INDUSTRY REPRESENTATIVES FOR CER BOARD
July 16, 2010
The Plasma Protein Therapeutics Association (PPTA) has nominated industry experts Mary Gustafson and Dr. Albert Farrugia for consideration for the Board of Governors for the Patient-Centered Outcomes Research Institute (PCORI) to help guide the Board in its decisions regarding the treatment of individuals with rare diseases. PPTA is a global trade association that represents the manufacturers of plasma-derived and recombinant biological therapies, collectively known as plasma protein therapies.
|
|
more >>
|
| |
|
|
PPTA TESTIFIES AT FDA PUBLIC HEARING ON RARE DISEASES
July 14, 2010
Providing information and context for the needs of patients suffering from rare diseases that require plasma protein therapies, the Plasma Protein Therapeutics Association (PPTA) presented at the recent U.S. Food and Drug Administration (FDA) public hearing, “Considerations Regarding Food and Drug Administration Review and Regulation of Articles for Treatment of Rare Diseases.”
|
|
more >>
|
| |
|
|
Statement on Review - Intravenous Alpha-1 Antitrypsin Augmentation Therapy
July 8, 2010
The article ‘Intravenous Alpha-1 Antitrypsin (AAT) augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease’ by Drs. PC Gotzsche and HK Johansen claims that treatment of patients with AAT concentrate confers no benefit. This article is published by the Cochrane Collaboration as a ‘Review,’ which is generally taken to mean a comprehensive survey of a particular area of therapeutics. In this instance the ‘Review’ comprises analysis of just two clinical trials, both of them from the same group of investigators in Copenhagen, Denmark. In no sense can this ‘Review’ be considered as representative of the field of AAT augmentation therapy. It is questionable whether this ‘Review’ meets the criteria for publication in peer reviewed journals.
|
|
more >>
|
| |
|
|
Ruedi Waeger Wins Robert W. Reilly Award 2010
June 18, 2010
The Plasma Protein Therapeutics Association (PPTA) is pleased to announce it has elected Ruedi Waeger as the winner of the 2010 Robert W. Reilly Award. The award was handed out at the Plasma Protein Forum in Reston, Virginia on June 15.
|
|
more >>
|
| |
|
|
PPTA Statement: Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and Plasma Protein Therapies
April 7, 2010
April 7, 2010 - PPTA members are committed to providing safe and effective therapies. PPTA understands that people who rely on plasma protein therapies may have concerns about the possible transmission of xenotropic murine leukemia virus-related virus (XMRV) through these therapies. XMRV was first isolated from human biological samples in 2006.1 It is a gamma-retrovirus that belongs to the viral family of Retroviridae, which are enveloped viruses.
|
|
more >>
|
| |
|
|
PPTA Statement on Signing of Health Care Reform Bill
March 30, 2010
March 30, 2010--“PPTA recognizes the historic achievement of President Obama and Congress in providing affordable, quality health care to millions of Americans. As the organization that represents the manufacturers of complex, biological therapies that treat extremely rare diseases and disorders, we have participated in the discussion surrounding health care reform for more than a year and have worked with Members of Congress to inform them of the unique nature of the industry and of the importance of preserving access for the fragile patient population our members serve.
|
|
more >>
|
| |
|
|
PLASMA COLLECTION INDUSTRY MEETS WITH STATE LEGISLATORS ABOUT THE IMPORTANCE OF LIFESAVING PLASMA DONATION
March 25, 2010
SAINT PAUL, Minn.—March 25, 2010—Today, employees from the state’s 12 plasma collection centers are meeting with key state legislators to inform them of the importance of lifesaving plasma used to treat rare, chronic diseases and of the thriving business that plasma collection centers contribute to the state.
|
|
more >>
|
| |
|
|
Kedrion Earns International Quality Certification For Manufacturing Lifesaving Plasma-Derived Therapies
February 5, 2010
ANNAPOLIS, MD (February 5, 2010) - The Plasma Protein Therapeutics Association (PPTA) announced today that Kedrion is the sixth company to be certified through its international Quality Standards of Excellence, Assurance, and Leadership (QSEAL) Program, which evaluates manufacturers of plasma protein therapies.
|
|
more >>
|
| |
|
|
PPTA Launches New Website Tool
September 23, 2009
ANNAPOLIS, MD (September 23, 2009) – Visitors to DonatingPlasma.org can more easily find their local plasma donation center now with an improved search feature. The Plasma Protein Therapeutics Association (PPTA), which developed the website to raise awareness of plasma donation, unveils the tool today, seeking to build on the importance of providing up-to-date information to donors who provide plasma needed to manufacture life-saving therapies.
|
|
more >>
|